Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib-thalidomide-dexamethasone induction with ixazomib vs placebo maintenance in transplant-ineligible newly diagnosed multiple myeloma
NL-OMON50234Phase 2Active, not recruiting
- Sponsor
- HOVON
- Start
- Nov 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ixazomib, thalidomide and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by HOVON. Primary endpoints: Progression-free survival from randomization and Overall response rate. Started Nov 2014; status: active, not recruiting.
02
Drugs
ixazomibthalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON50234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50234.